{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:50:07Z","timestamp":1790711407791,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T00:00:00Z","timestamp":1600387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T00:00:00Z","timestamp":1600387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Science Foundation of China","doi-asserted-by":"crossref","award":["81703431"],"award-info":[{"award-number":["81703431"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Science Foundation of China","doi-asserted-by":"crossref","award":["81673375"],"award-info":[{"award-number":["81673375"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s13346-020-00849-7","type":"journal-article","created":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T14:02:50Z","timestamp":1600437770000},"page":"1218-1235","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":81,"title":["Inhalable solid lipid nanoparticles for intracellular tuberculosis infection therapy: macrophage-targeting and pH-sensitive properties"],"prefix":"10.1007","volume":"11","author":[{"given":"Cheng","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weifen","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengwei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanbin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,18]]},"reference":[{"issue":"10","key":"849_CR1","doi-asserted-by":"publisher","first-page":"e327","DOI":"10.1016\/s1473-3099(17)30248-7","volume":"17","author":"PA LoBue","year":"2017","unstructured":"LoBue PA, Mermin JH. Latent tuberculosis infection: the final frontier of tuberculosis elimination in the USA. Lancet Infect Dis. 2017;17(10):e327\u2013e33. https:\/\/doi.org\/10.1016\/s1473-3099(17)30248-7.","journal-title":"Lancet Infect Dis"},{"key":"849_CR2","unstructured":"Organization WH. Global tuberculosis report 2019. 2019."},{"issue":"10202","key":"849_CR3","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/s0140-6736(19)32045-8","volume":"394","author":"A Reuter","year":"2019","unstructured":"Reuter A, Hughes J, Furin J. Challenges and controversies in childhood tuberculosis. Lancet. 2019;394(10202):967\u201378. https:\/\/doi.org\/10.1016\/s0140-6736(19)32045-8.","journal-title":"Lancet."},{"issue":"10178","key":"849_CR4","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/s0140-6736(19)30024-8","volume":"393","author":"MJA Reid","year":"2019","unstructured":"Reid MJA, Arinaminpathy N, Bloom A, Bloom BR, Boehme C, Chaisson R, et al. Building a tuberculosis-free world: the Lancet Commission on Tuberculosis. Lancet. 2019;393(10178):1331\u201384. https:\/\/doi.org\/10.1016\/s0140-6736(19)30024-8.","journal-title":"Lancet."},{"key":"849_CR5","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3389\/fimmu.2015.00313","volume":"6","author":"KP Fennelly","year":"2015","unstructured":"Fennelly KP, Jones-Lopez EC. Quantity and quality of inhaled dose predicts immunopathology in tuberculosis. Front Immunol. 2015;6:313. https:\/\/doi.org\/10.3389\/fimmu.2015.00313.","journal-title":"Front Immunol"},{"issue":"43","key":"849_CR6","doi-asserted-by":"publisher","first-page":"729","DOI":"10.3238\/arztebl.2019.0729","volume":"116","author":"I Suarez","year":"2019","unstructured":"Suarez I, Funger SM, Kroger S, Rademacher J, Fatkenheuer G, Rybniker J. The diagnosis and treatment of tuberculosis. Dtsch Arztebl Int. 2019;116(43):729\u201335. https:\/\/doi.org\/10.3238\/arztebl.2019.0729.","journal-title":"Dtsch Arztebl Int"},{"issue":"1","key":"849_CR7","doi-asserted-by":"publisher","first-page":"e03030","DOI":"10.1016\/j.heliyon.2019.e03030","volume":"6","author":"Fatmawati","year":"2020","unstructured":"Fatmawati, Dyah Purwati U, Riyudha F, Tasman H. Optimal control of a discrete age-structured model for tuberculosis transmission. Heliyon. 2020;6(1):e03030. https:\/\/doi.org\/10.1016\/j.heliyon.2019.e03030.","journal-title":"Heliyon"},{"issue":"4\u20135","key":"849_CR8","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/s0098-2997(01)00010-3","volume":"22","author":"HJ Forman","year":"2001","unstructured":"Forman HJ, Torres M. Redox signaling in macrophages. Mol Asp Med. 2001;22(4\u20135):189\u2013216. https:\/\/doi.org\/10.1016\/s0098-2997(01)00010-3.","journal-title":"Mol Asp Med"},{"key":"849_CR9","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3389\/fmicb.2011.00105","volume":"2","author":"MI Voskuil","year":"2011","unstructured":"Voskuil MI, Bartek IL, Visconti K, Schoolnik GK. The response of Mycobacterium tuberculosis to reactive oxygen and nitrogen species. Front Microbiol. 2011;2:105. https:\/\/doi.org\/10.3389\/fmicb.2011.00105.","journal-title":"Front Microbiol"},{"key":"849_CR10","doi-asserted-by":"publisher","first-page":"4599","DOI":"10.1111\/bph.14867","volume":"176","author":"SR Khan","year":"2019","unstructured":"Khan SR, Manialawy Y, Siraki AG. Isoniazid and host immune system interactions: a proposal for a novel comprehensive mode of action. Br J Pharmacol. 2019;176:4599\u2013608. https:\/\/doi.org\/10.1111\/bph.14867.","journal-title":"Br J Pharmacol"},{"issue":"22","key":"849_CR11","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1056\/NEJMra1405427","volume":"372","author":"H Getahun","year":"2015","unstructured":"Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis infection. N Engl J Med. 2015;372(22):2127\u201335. https:\/\/doi.org\/10.1056\/NEJMra1405427.","journal-title":"N Engl J Med"},{"key":"849_CR12","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ejpb.2018.10.020","volume":"134","author":"G O'Connor","year":"2019","unstructured":"O'Connor G, Krishnan N, Fagan-Murphy A, Cassidy J, O'Leary S, Robertson BD, et al. Inhalable poly(lactic-co-glycolic acid) (PLGA) microparticles encapsulating all-trans-retinoic acid (ATRA) as a host-directed, adjunctive treatment for Mycobacterium tuberculosis infection. Eur J Pharm Biopharm. 2019;134:153\u201365. https:\/\/doi.org\/10.1016\/j.ejpb.2018.10.020.","journal-title":"Eur J Pharm Biopharm"},{"issue":"4","key":"849_CR13","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1093\/femsre\/fuz006","volume":"43","author":"C Bussi","year":"2019","unstructured":"Bussi C, Gutierrez MG. Mycobacterium tuberculosis infection of host cells in space and time. FEMS Microbiol Rev. 2019;43(4):341\u201361. https:\/\/doi.org\/10.1093\/femsre\/fuz006.","journal-title":"FEMS Microbiol Rev"},{"issue":"4","key":"849_CR14","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.tube.2015.04.003","volume":"95","author":"P Salgame","year":"2015","unstructured":"Salgame P, Geadas C, Collins L, Jones-Lopez E, Ellner JJ. Latent tuberculosis infection--revisiting and revising concepts. Tuberculosis. 2015;95(4):373\u201384. https:\/\/doi.org\/10.1016\/j.tube.2015.04.003.","journal-title":"Tuberculosis."},{"key":"849_CR15","first-page":"28","volume":"26","author":"SH Ferebee","year":"1970","unstructured":"Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc. 1970;26:28\u2013106.","journal-title":"Bibl Tuberc"},{"issue":"23","key":"849_CR16","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1056\/NEJMcp021045","volume":"347","author":"RM Jasmer","year":"2002","unstructured":"Jasmer RM, Nahid P, Hopewell PC. Clinical practice. Latent tuberculosis infection. N Engl J Med. 2002;347(23):1860\u20136. https:\/\/doi.org\/10.1056\/NEJMcp021045.","journal-title":"N Engl J Med"},{"key":"849_CR17","doi-asserted-by":"publisher","first-page":"CD001363","DOI":"10.1002\/14651858.CD001363","volume":"2","author":"MJ Smieja","year":"2000","unstructured":"Smieja MJ, Marchetti CA, Cook DJ, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev. 2000;2:CD001363. https:\/\/doi.org\/10.1002\/14651858.CD001363.","journal-title":"Cochrane Database Syst Rev"},{"issue":"RR-6","key":"849_CR18","first-page":"1","volume":"49","author":"AT Society","year":"2000","unstructured":"Society AT. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep. 2000;49(RR-6):1\u201351.","journal-title":"MMWR Recomm Rep"},{"issue":"2","key":"849_CR19","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1378\/chest.09-0394","volume":"137","author":"CR Horsburgh Jr","year":"2010","unstructured":"Horsburgh CR Jr, Goldberg S, Bethel J, Chen S, Colson PW, Hirsch-Moverman Y, et al. Latent TB infection treatment acceptance and completion in the United States and Canada. Chest. 2010;137(2):401\u20139. https:\/\/doi.org\/10.1378\/chest.09-0394.","journal-title":"Chest."},{"issue":"2","key":"849_CR20","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.amepre.2018.04.030","volume":"55","author":"GJ Njie","year":"2018","unstructured":"Njie GJ, Morris SB, Woodruff RY, Moro RN, Vernon AA, Borisov AS. Isoniazid-rifapentine for latent tuberculosis infection: a systematic review and meta-analysis. Am J Prev Med. 2018;55(2):244\u201352. https:\/\/doi.org\/10.1016\/j.amepre.2018.04.030.","journal-title":"Am J Prev Med"},{"issue":"4","key":"849_CR21","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1021\/mp300043f","volume":"9","author":"R Kumar Verma","year":"2012","unstructured":"Kumar Verma R, Mukker JK, Singh RS, Kumar K, Verma PR, Misra A. Partial biodistribution and pharmacokinetics of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to rhesus macaques. Mol Pharm. 2012;9(4):1011\u20136. https:\/\/doi.org\/10.1021\/mp300043f.","journal-title":"Mol Pharm"},{"issue":"1","key":"849_CR22","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/btm2.10112","volume":"4","author":"PS Jahagirdar","year":"2019","unstructured":"Jahagirdar PS, Gupta PK, Kulkarni SP, Devarajan PV. Polymeric curcumin nanoparticles by a facile in situ method for macrophage targeted delivery. Bioeng Transl Med. 2019;4(1):141\u201351. https:\/\/doi.org\/10.1002\/btm2.10112.","journal-title":"Bioeng Transl Med"},{"issue":"22","key":"849_CR23","doi-asserted-by":"publisher","first-page":"20304","DOI":"10.1021\/acsami.8b22693","volume":"11","author":"H Ren","year":"2019","unstructured":"Ren H, He Y, Liang J, Cheng Z, Zhang M, Zhu Y, et al. Role of liposome size, surface charge, and PEGylation on rheumatoid arthritis targeting therapy. ACS Appl Mater Interfaces. 2019;11(22):20304\u201315. https:\/\/doi.org\/10.1021\/acsami.8b22693.","journal-title":"ACS Appl Mater Interfaces"},{"key":"849_CR24","doi-asserted-by":"publisher","first-page":"110709","DOI":"10.1016\/j.colsurfb.2019.110709","volume":"186","author":"M Cicuendez","year":"2019","unstructured":"Cicuendez M, Fernandes M, Ayan-Varela M, Oliveira H, Feito MJ, Diez-Orejas R, et al. Macrophage inflammatory and metabolic responses to graphene-based nanomaterials differing in size and functionalization. Colloids Surf B: Biointerfaces. 2019;186:110709. https:\/\/doi.org\/10.1016\/j.colsurfb.2019.110709.","journal-title":"Colloids Surf B: Biointerfaces"},{"issue":"6","key":"849_CR25","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.addr.2013.01.002","volume":"65","author":"A des Rieux","year":"2013","unstructured":"des Rieux A, Pourcelle V, Cani PD, Marchand-Brynaert J, Preat V. Targeted nanoparticles with novel non-peptidic ligands for oral delivery. Adv Drug Deliv Rev. 2013;65(6):833\u201344. https:\/\/doi.org\/10.1016\/j.addr.2013.01.002.","journal-title":"Adv Drug Deliv Rev"},{"issue":"12","key":"849_CR26","doi-asserted-by":"publisher","first-page":"4013","DOI":"10.1021\/acs.biomac.5b01380","volume":"16","author":"RS Loka","year":"2015","unstructured":"Loka RS, McConnell MS, Nguyen HM. Studies of highly-ordered heterodiantennary mannose\/glucose-functionalized polymers and concanavalin a protein interactions using isothermal titration calorimetry. Biomacromolecules. 2015;16(12):4013\u201321. https:\/\/doi.org\/10.1021\/acs.biomac.5b01380.","journal-title":"Biomacromolecules."},{"issue":"9","key":"849_CR27","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.1128\/AAC.00153-08","volume":"52","author":"RK Verma","year":"2008","unstructured":"Verma RK, Kaur J, Kumar K, Yadav AB, Misra A. Intracellular time course, pharmacokinetics, and biodistribution of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to mice. Antimicrob Agents Chemother. 2008;52(9):3195\u2013201. https:\/\/doi.org\/10.1128\/AAC.00153-08.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"849_CR28","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.tube.2004.11.003","volume":"85","author":"R Pandey","year":"2005","unstructured":"Pandey R, Khuller GK. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis. 2005;85(4):227\u201334. https:\/\/doi.org\/10.1016\/j.tube.2004.11.003.","journal-title":"Tuberculosis."},{"issue":"23","key":"849_CR29","doi-asserted-by":"publisher","first-page":"e1900965","DOI":"10.1002\/adhm.201900965","volume":"8","author":"Y Yang","year":"2019","unstructured":"Yang Y, Huang Z, Li J, Mo Z, Huang Y, Ma C, et al. PLGA porous microspheres dry powders for codelivery of afatinib-loaded solid lipid nanoparticles and paclitaxel: novel therapy for EGFR tyrosine kinase inhibitors resistant nonsmall cell lung cancer. Adv Healthc Mater. 2019;8(23):e1900965. https:\/\/doi.org\/10.1002\/adhm.201900965.","journal-title":"Adv Healthc Mater"},{"issue":"1","key":"849_CR30","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1208\/s12249-019-1552-3","volume":"21","author":"P Marcianes","year":"2019","unstructured":"Marcianes P, Negro S, Barcia E, Montejo C, Fernandez-Carballido A. Potential active targeting of gatifloxacin to macrophages by means of surface-modified PLGA microparticles destined to treat tuberculosis. AAPS PharmSciTech. 2019;21(1):15. https:\/\/doi.org\/10.1208\/s12249-019-1552-3.","journal-title":"AAPS PharmSciTech"},{"issue":"4","key":"849_CR31","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s11095-019-2596-5","volume":"36","author":"L Pang","year":"2019","unstructured":"Pang L, Pei Y, Uzunalli G, Hyun H, Lyle LT, Yeo Y. Surface modification of polymeric nanoparticles with M2pep peptide for drug delivery to tumor-associated macrophages. Pharm Res. 2019;36(4):65. https:\/\/doi.org\/10.1007\/s11095-019-2596-5.","journal-title":"Pharm Res"},{"issue":"11","key":"849_CR32","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1002\/adhm.201600070","volume":"5","author":"C Yang","year":"2016","unstructured":"Yang C, Krishnamurthy S, Liu J, Liu S, Lu X, Coady DJ, et al. Broad-spectrum antimicrobial star polycarbonates functionalized with mannose for targeting bacteria residing inside immune cells. Adv Healthc Mater. 2016;5(11):1272\u201381. https:\/\/doi.org\/10.1002\/adhm.201600070.","journal-title":"Adv Healthc Mater"},{"issue":"13","key":"849_CR33","doi-asserted-by":"publisher","first-page":"e1701395","DOI":"10.1002\/adhm.201701395","volume":"7","author":"LC Lin","year":"2018","unstructured":"Lin LC, Chattopadhyay S, Lin JC, Hu CJ. Advances and opportunities in nanoparticle- and nanomaterial-based vaccines against bacterial infections. Adv Healthc Mater. 2018;7(13):e1701395. https:\/\/doi.org\/10.1002\/adhm.201701395.","journal-title":"Adv Healthc Mater"},{"key":"849_CR34","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.ejpb.2019.01.022","volume":"136","author":"G Tripodo","year":"2019","unstructured":"Tripodo G, Perteghella S, Grisoli P, Trapani A, Torre ML, Mandracchia D. Drug delivery of rifampicin by natural micelles based on inulin: physicochemical properties, antibacterial activity and human macrophages uptake. Eur J Pharm Biopharm. 2019;136:250\u20138. https:\/\/doi.org\/10.1016\/j.ejpb.2019.01.022.","journal-title":"Eur J Pharm Biopharm"},{"key":"849_CR35","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jcis.2016.07.020","volume":"481","author":"N Soni","year":"2016","unstructured":"Soni N, Soni N, Pandey H, Maheshwari R, Kesharwani P, Tekade RK. Augmented delivery of gemcitabine in lung cancer cells exploring mannose anchored solid lipid nanoparticles. J Colloid Interface Sci. 2016;481:107\u201316. https:\/\/doi.org\/10.1016\/j.jcis.2016.07.020.","journal-title":"J Colloid Interface Sci"},{"key":"849_CR36","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/nano10030568","volume":"10","author":"E Truzzi","year":"2020","unstructured":"Truzzi E, Nascimento TL, Iannuccelli V, Costantino L, Lima EM, Leo E, et al. In vivo biodistribution of respirable solid lipid nanoparticles surface-decorated with a mannose-based surfactant: a promising tool for pulmonary tuberculosis treatment? Nanomaterials (Basel). 2020;10:3. https:\/\/doi.org\/10.3390\/nano10030568.","journal-title":"Nanomaterials (Basel)"},{"issue":"8","key":"849_CR37","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1007\/s11095-010-0149-z","volume":"27","author":"W Yu","year":"2010","unstructured":"Yu W, Liu C, Liu Y, Zhang N, Xu W. Mannan-modified solid lipid nanoparticles for targeted gene delivery to alveolar macrophages. Pharm Res. 2010;27(8):1584\u201396. https:\/\/doi.org\/10.1007\/s11095-010-0149-z.","journal-title":"Pharm Res"},{"issue":"4","key":"849_CR38","doi-asserted-by":"publisher","first-page":"640","DOI":"10.3109\/03639045.2014.891130","volume":"41","author":"PK Sahu","year":"2015","unstructured":"Sahu PK, Mishra DK, Jain N, Rajoriya V, Jain AK. Mannosylated solid lipid nanoparticles for lung-targeted delivery of paclitaxel. Drug Dev Ind Pharm. 2015;41(4):640\u20139. https:\/\/doi.org\/10.3109\/03639045.2014.891130.","journal-title":"Drug Dev Ind Pharm"},{"key":"849_CR39","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ejps.2017.12.006","volume":"114","author":"A Costa","year":"2018","unstructured":"Costa A, Sarmento B, Seabra V. Mannose-functionalized solid lipid nanoparticles are effective in targeting alveolar macrophages. Eur J Pharm Sci. 2018;114:103\u201313. https:\/\/doi.org\/10.1016\/j.ejps.2017.12.006.","journal-title":"Eur J Pharm Sci"},{"issue":"sup1","key":"849_CR40","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1080\/21691401.2018.1434186","volume":"46","author":"ACC Vieira","year":"2018","unstructured":"Vieira ACC, Chaves LL, Pinheiro M, Lima SAC, Ferreira D, Sarmento B, et al. Mannosylated solid lipid nanoparticles for the selective delivery of rifampicin to macrophages. Artif Cells Nanomed Biotechnol. 2018;46(sup1):653\u201363. https:\/\/doi.org\/10.1080\/21691401.2018.1434186.","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"849_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.chemphyslip.2015.03.003","volume":"188","author":"I Singh","year":"2015","unstructured":"Singh I, Swami R, Jeengar MK, Khan W, Sistla R. p-Aminophenyl-alpha-D-mannopyranoside engineered lipidic nanoparticles for effective delivery of docetaxel to brain. Chem Phys Lipids. 2015;188:1\u20139. https:\/\/doi.org\/10.1016\/j.chemphyslip.2015.03.003.","journal-title":"Chem Phys Lipids"},{"issue":"6","key":"849_CR42","doi-asserted-by":"publisher","first-page":"5121","DOI":"10.1021\/acsnano.7b09041","volume":"12","author":"R Yang","year":"2018","unstructured":"Yang R, Xu J, Xu L, Sun X, Chen Q, Zhao Y, et al. Cancer cell membrane-coated adjuvant nanoparticles with mannose modification for effective anticancer vaccination. ACS Nano. 2018;12(6):5121\u20139. https:\/\/doi.org\/10.1021\/acsnano.7b09041.","journal-title":"ACS Nano"},{"issue":"2","key":"849_CR43","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.nano.2017.11.015","volume":"14","author":"X Ke","year":"2018","unstructured":"Ke X, Yang C, Cheng W, Yang YY. Delivery of NF-kappaB shRNA using carbamate-mannose modified PEI for eliminating cancer stem cells. Nanomedicine. 2018;14(2):405\u201314. https:\/\/doi.org\/10.1016\/j.nano.2017.11.015.","journal-title":"Nanomedicine."},{"issue":"2","key":"849_CR44","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s00253-014-6147-z","volume":"99","author":"Z Cui","year":"2015","unstructured":"Cui Z, Han D, Sun X, Zhang M, Feng X, Sun C, et al. Mannose-modified chitosan microspheres enhance OprF-OprI-mediated protection of mice against Pseudomonas aeruginosa infection via induction of mucosal immunity. Appl Microbiol Biotechnol. 2015;99(2):667\u201380. https:\/\/doi.org\/10.1007\/s00253-014-6147-z.","journal-title":"Appl Microbiol Biotechnol"},{"issue":"1","key":"849_CR45","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1128\/IAI.66.1.28-35.1998","volume":"66","author":"J Bernardo","year":"1998","unstructured":"Bernardo J, Billingslea AM, Blumenthal RL, Seetoo KF, Simons ER, Fenton MJ. Differential responses of human mononuclear phagocytes to mycobacterial lipoarabinomannans: role of CD14 and the mannose receptor. Infect Immun. 1998;66(1):28\u201335.","journal-title":"Infect Immun"},{"issue":"3","key":"849_CR46","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/jlb.41.3.248","volume":"41","author":"I Takata","year":"1987","unstructured":"Takata I, Chida K, Gordon MR, Myrvik QN, Ricardo MJ Jr, Kucera LS. L-fucose, D-mannose, L-galactose, and their BSA conjugates stimulate macrophage migration. J Leukoc Biol. 1987;41(3):248\u201356. https:\/\/doi.org\/10.1002\/jlb.41.3.248.","journal-title":"J Leukoc Biol"},{"issue":"3","key":"849_CR47","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/jlb.42.3.197","volume":"42","author":"MR Gordon","year":"1987","unstructured":"Gordon MR, Chida K, Takata I, Myrvik QN. Macrophage migration inhibition induced by MDP, LPS, PMA, and MIF\/MAF: reversal by macrophage migration enhancement factor (MEF), L-fucose, L-fucosyl BSA, D-mannose, and D-mannosyl BSA. J Leukoc Biol. 1987;42(3):197\u2013203. https:\/\/doi.org\/10.1002\/jlb.42.3.197.","journal-title":"J Leukoc Biol"},{"issue":"3","key":"849_CR48","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1189\/jlb.0107053","volume":"82","author":"J Sturge","year":"2007","unstructured":"Sturge J, Todd SK, Kogianni G, McCarthy A, Isacke CM. Mannose receptor regulation of macrophage cell migration. J Leukoc Biol. 2007;82(3):585\u201393. https:\/\/doi.org\/10.1189\/jlb.0107053.","journal-title":"J Leukoc Biol"},{"issue":"1","key":"849_CR49","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.tube.2010.08.009","volume":"91","author":"A Misra","year":"2011","unstructured":"Misra A, Hickey AJ, Rossi C, Borchard G, Terada H, Makino K, et al. Inhaled drug therapy for treatment of tuberculosis. Tuberculosis (Edinb). 2011;91(1):71\u201381. https:\/\/doi.org\/10.1016\/j.tube.2010.08.009.","journal-title":"Tuberculosis (Edinb)"}],"updated-by":[{"DOI":"10.1007\/s13346-022-01160-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T00:00:00Z","timestamp":1650326400000}}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-020-00849-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-020-00849-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-020-00849-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T19:24:45Z","timestamp":1650482685000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-020-00849-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,18]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["849"],"URL":"https:\/\/doi.org\/10.1007\/s13346-020-00849-7","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s13346-022-01160-3","asserted-by":"object"}]},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,18]]},"assertion":[{"value":"28 August 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2022","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s13346-022-01160-3","URL":"https:\/\/doi.org\/10.1007\/s13346-022-01160-3","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All authors declare the experiments comply with the current laws of China. The in vivo tests were assessed based on Wistar rats, which were purchased from Southern Medical University Laboratory Animal Center. The in vivo animal tests were approved by the institutional animal care and use committee of Sun Yat-sen University (No. SYSU-IACUC-2019-000308).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"N\/A","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}